Beyond antiplatelets and anticoagulants, the pharmacology of stroke prevention encompasses statins, blood pressure control, glucose management, and a growing array of emerging therapies. Modern secondary stroke prevention demands aggressive multi-modal pharmacologic risk factor control, with strong evidence that intensive lipid lowering, BP control, and metabolic management each independently and additively reduce recurrent stroke. This page covers statins, lipid-lowering, BP management, diabetes pharmacology in stroke patients, and emerging neuroprotection.

Statins (HMG-CoA Reductase Inhibitors)

Mechanism

  • Inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis.
  • Reduce hepatic cholesterol → upregulate LDL receptors → reduce serum LDL.
  • Pleiotropic effects: anti-inflammatory, plaque stabilization, endothelial function improvement.

High-Intensity vs Moderate-Intensity

  • High-intensity (≥50% LDL reduction): atorvastatin 40-80 mg, rosuvastatin 20-40 mg.
  • Moderate-intensity (30-49% LDL reduction): atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg, pravastatin 40-80 mg.

Uses in Stroke Prevention

  • SPARCL trial: atorvastatin 80 mg reduced recurrent stroke after non-cardioembolic stroke/TIA.
  • Guideline: high-intensity statin for all atherosclerotic stroke/TIA (target LDL <70 or <55 for very high risk).
  • Some benefit in cardioembolic stroke (concurrent ASCVD risk).
  • Cardioembolic stroke from AF alone (no atherosclerosis): less clear; consider for CVD risk.

Side Effects

  • Myopathy: mild myalgias (common), rhabdomyolysis (rare).
  • Hepatic enzyme elevation: usually mild; severe liver injury rare.
  • Diabetes: small increase in incident type 2 DM, especially high-dose.
  • Cognitive effects: often reported, generally mild, evidence mixed.
  • Hemorrhagic stroke risk: small absolute increase in SPARCL — does not contraindicate use.

Drug Interactions

  • Simvastatin and lovastatin: CYP3A4 metabolism; many interactions.
  • Pravastatin, rosuvastatin: less CYP-dependent.
  • Atorvastatin: CYP3A4 but less affected than simvastatin.
  • Gemfibrozil + statins: risk of myopathy (contraindicated in some).

Non-Statin Lipid Lowering

Ezetimibe

  • Blocks intestinal cholesterol absorption (NPC1L1).
  • 10 mg daily; add to statin for additional LDL reduction.
  • IMPROVE-IT trial: reduced cardiovascular events.
  • Generally well-tolerated.

PCSK9 Inhibitors

  • Evolocumab (Repatha), alirocumab (Praluent): monoclonal antibodies; SC every 2-4 weeks.
  • Reduce LDL by 50-60% over statin alone.
  • FOURIER, ODYSSEY-OUTCOMES: reduced cardiovascular events.
  • Use: ASCVD on max statin + ezetimibe with LDL above target (very high risk: <55 mg/dL).
  • Cost still significant; coverage requires prior auth.

Bempedoic Acid

  • ATP-citrate lyase inhibitor; reduces cholesterol synthesis (alternative target to HMG-CoA).
  • Used in statin-intolerant patients; partial LDL reduction.
  • CLEAR Outcomes: cardiovascular benefit.

Inclisiran

  • Small interfering RNA (siRNA) targeting PCSK9 mRNA.
  • SC every 6 months — striking dosing convenience.
  • 50%+ LDL reduction.

Other

  • Fibrates (gemfibrozil, fenofibrate): triglyceride reduction; some HDL increase; modest LDL effect.
  • Omega-3 fatty acids (icosapent ethyl, EPA): REDUCE-IT trial showed cardiovascular benefit.
  • Niacin: rarely used (limited cardiovascular benefit when added to statin).
  • Bile acid sequestrants: limited use.

Blood Pressure Management

Acute Stroke BP

  • Ischemic stroke not receiving tPA: permissive hypertension to SBP <220 / DBP <120 (allows penumbral perfusion).
  • Ischemic stroke receiving tPA: SBP <185 / DBP <110 before tPA; <180 / <105 during/after.
  • Hemorrhagic stroke: target SBP <140 (INTERACT-2, ATACH-2); rapid lowering safe and effective.
  • Subarachnoid hemorrhage: prevent re-bleeding; SBP <160 generally; target depends on patient.

Acute BP Lowering Drugs

  • Labetalol IV: 10-20 mg bolus q10 min; α + β blocker; rapid onset.
  • Nicardipine IV infusion: 5-15 mg/hour; titratable Ca channel blocker.
  • Hydralazine IV: 5-20 mg q15 min; rarely first-line (reflex tachycardia).
  • Sodium nitroprusside: rapid; cyanide risk; reserve for refractory.
  • Clevidipine: ultra-short-acting Ca blocker; ICU.

Secondary Stroke Prevention BP

  • Target: <130/80 mmHg generally; <120/80 in selected high-risk patients (per recent guidelines).
  • First-line: thiazide (chlorthalidone preferred), ACE inhibitor, or ARB.
  • Combinations: thiazide + ACE/ARB; add CCB if needed.
  • African ancestry: thiazide and CCB more effective; ACE inhibitor less.
  • Lacunar stroke: aggressive BP control most beneficial.

Diabetes Management

  • Target HbA1c ~7% (individualized).
  • Metformin: first-line if no contraindication.
  • SGLT2 inhibitors (empagliflozin, dapagliflozin): cardiovascular and renal benefit; reduce CV events including stroke in some studies.
  • GLP-1 agonists (semaglutide, liraglutide): cardiovascular benefit; reduce stroke (REWIND trial).
  • DPP-4 inhibitors: neutral cardiovascular effect.
  • Sulfonylureas, TZDs: less preferred now.
  • Insulin: when needed; hypoglycemia risk.

Other Cardiovascular Risk Pharm

Aldosterone Antagonists

  • Spironolactone, eplerenone: HF; resistant HTN; some renal benefit.

Aspirin Primary Prevention

  • Generally NOT recommended for primary prevention except very high-risk patients.
  • USPSTF 2022: consider in patients aged 40-59 with 10-year ASCVD ≥10% and low bleeding risk.

Acute Reperfusion Therapy

IV Thrombolysis

  • Alteplase (tPA): 0.9 mg/kg (max 90 mg); 10% bolus, 90% over 60 min; within 4.5 hours.
  • Tenecteplase: 0.25 mg/kg single bolus; emerging as preferred (similar/better than tPA in some trials).
  • Strict exclusion criteria; goal: door-to-needle <60 min, ideally <45 min.
  • ICH risk ~6% symptomatic.

Mechanical Thrombectomy

  • For large vessel occlusion: within 6 hours; selected up to 24 hours with imaging (DAWN, DEFUSE-3).
  • Stent retriever or aspiration.
  • Most powerful intervention available for ischemic stroke.

Neuroprotection (Emerging)

  • Numerous trials have failed to demonstrate benefit (NXY-059, citicoline, free radical scavengers in past).
  • Edaravone: free radical scavenger; FDA-approved for ALS; trials in stroke ongoing.
  • Nerinetide (NA-1): postsynaptic density inhibitor; mixed results; trial ongoing.
  • Other approaches: stem cells, mild hypothermia (limited clinical evidence), ischemic conditioning.
  • Currently: best stroke neuroprotection = rapid reperfusion + standard care.

🔍 Did You Know?

The PCSK9 inhibitor era has fundamentally changed the landscape of LDL lowering and secondary prevention in stroke and atherosclerosis. Evolocumab and alirocumab — monoclonal antibodies that block PCSK9, the protein that downregulates hepatic LDL receptors — produce 50-60% additional LDL reduction beyond maximum statin therapy, achieving LDL levels of 30-50 mg/dL or lower. In FOURIER and ODYSSEY-OUTCOMES, these agents reduced cardiovascular events including stroke in patients with atherosclerotic CVD. The newer agent inclisiran, an siRNA that silences PCSK9 mRNA, achieves similar reductions with the remarkable advantage of only twice-yearly dosing — a dramatic improvement in adherence potential. This has prompted reconsideration of LDL targets: many guidelines now recommend LDL <55 mg/dL for very high-risk patients (recurrent ASCVD, multiple risk factors), and some clinicians push lower. The lesson generalizes: pharmacologic targets for biomarker-driven diseases are evolving as more effective drugs become available, and “lower is better” has emerged as the dominant paradigm for LDL. For stroke neurologists, the practical question is when to escalate from statin + ezetimibe to PCSK9 inhibitor — for recurrent atherosclerotic stroke or stroke + CAD with LDL >70 on max statin, the answer is increasingly “now” rather than “later.” Cost barriers are significant but coverage is improving, and the benefit-risk is favorable.

Pitfalls and Pearls

  • High-intensity statin: all atherosclerotic stroke/TIA; target LDL <70 (or <55 high risk).
  • Statin pleiotropic effects: plaque stabilization, anti-inflammatory; benefit beyond LDL.
  • SPARCL: atorvastatin 80 mg in stroke/TIA — reduced recurrent stroke.
  • Ezetimibe: add to statin for additional LDL reduction.
  • PCSK9 inhibitors: 50-60% additional LDL reduction; high-risk patients.
  • Inclisiran: siRNA; twice-yearly dosing; striking convenience.
  • Acute IS BP: permissive hypertension to 220/120 if no tPA; <185/110 if tPA.
  • Acute ICH BP: target SBP <140; rapid lowering safe (INTERACT-2, ATACH-2).
  • Long-term BP: target <130/80; thiazide (chlorthalidone) + ACE/ARB first-line.
  • Lacunar stroke: aggressive BP control particularly beneficial.
  • SGLT2 inhibitors, GLP-1 agonists: cardiovascular and stroke benefit beyond glucose lowering.
  • Aspirin primary prevention: limited indication; USPSTF restricts.
  • tPA window: 4.5 hours from last known well.
  • Tenecteplase: emerging preferred thrombolytic; single bolus.
  • Mechanical thrombectomy: 6-24 hours for LVO with imaging.
  • Best stroke neuroprotection: rapid reperfusion + standard care.

References

  1. Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack (SPARCL). N Engl J Med. 2006;355(6):549-559.
  2. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease (FOURIER). N Engl J Med. 2017;376(18):1713-1722.
  3. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke. Stroke. 2021;52(7):e364-e467.
  4. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update. Stroke. 2019;50(12):e344-e418.
  5. Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage (INTERACT-2). N Engl J Med. 2013;368(25):2355-2365.
  6. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016;375(4):311-322.